Tenelia Tab. 20mg

Ingredient

Teneligliptin Hydrobromide Hydrate

Content

Teneligliptin Hydrobromide Hydrate 31mg (20mg as Teneligliptin)

Indication

This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes.
– Monotherapy
– Combination therapy

Toviaz SR Tab.

Ingredient

Fesoterodine fumarate

Content

Toviaz SR Tab. 4mg: Fesoterodine fumarate 4mg
Toviaz SR Tab. 8mg: Fesoterodine fumarate 8mg

Indication

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

Trental SR Tab. 400

Ingredient

Pentoxifylline

Content

400mg

Indication

1) Improvement of cerebral circulation disorder (ischemia or post stroke symptoms and symptoms of cerebral arteriosclerosis like dizziness, headache, amnesia, and so on)
2) Improvement of eye circulation disorder
3) Improvement of peripheral arterial circulation disorder (Intermittent claudication, pain at rest, diabetic angiopathy, kraurosis, and vascular neuropathy)

Triapin Tab.

Ingredient

Felodipine/Ramipril

Content

2.5mg/2.5mg, 5mg/5mg

Indication

Treatment of essential hypertension.

Tritace Protect Tab.

Ingredient

Hydroxypropylmethylcellulose-coated Ramipril Granule

Content

11.765mg (10mg as Ramipril)

Indication

1) Treatment of hypertension
2) Treatment of heart failure post myocardial infarction
3) Reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in patients over 55 years of age with clinical evidence of cardiovascular disease (myocardial infarction, unstable angina, past history of polyvascular coronary bypass graft or polyvascular percutaneous coronary angioplasty), stroke or peripheral vascular disease. Also reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in diabetic patients over 55 years of age who have one or more of the following clinical symptoms: Hypertension (systolic blood pressure exceeds 160mmHg or diastolic blood pressure exceeds 90 mmHg), high total cholesterol level (above 5.2 mmol/L), low high-density lipoprotein level (less than 0.9 mmol/L), smoker, history of microalbuminuria or past vascular disease
4) Treatment of the following clinical symptoms in diabetic patients: Early nephropathy with microalbuminuria (30­300mg/24h), overt glomerular nephropathy, proteinuria (>500mg/24h)
– Treatment of non-diabetic overt glomerular nephropathy (when creatinine clearance is 20-70 mL/min) or proteinuria (≥3g/24h)

Tritace Tab.

Ingredient

Ramipril

Content

2.5mg, 5mg

Indication

1) Treatment of hypertension.
2) Treatment of heart failure post myocardial infarction
3) Reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in patients over 55 years of age with clinical evidence of cardiovascular disease (myocardial infarction, unstable angina, past history of polyvascular coronary bypass graft or polyvascular percutaneous coronary angioplasty), stroke or peripheral vascular disease. Also reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in diabetic patients over 55 years of age who have one or more of the following clinical symptoms: Hypertension (systolic blood pressure exceeds 160mmHg or diastolic blood pressure exceeds 90 mmHg), high total cholesterol level (above 5.2 mmol/L), low high-density lipoprotein level (less than 0.9 mmol/L), smoker, history of microalbuminuria or past vascular disease
4) Treatment of the following clinical symptoms in diabetic patients: Early nephropathy with microalbuminuria (30­300mg/24h), overt glomerular nephropathy, proteinuria (>500mg/24h)
– Treatment of non-diabetic overt glomerular nephropathy (when creatinine clearance is 20-70 mL/min) or proteinuria (≥3g/24h)

VaxigripTetra

Ingredient

A/Victoria/2570/2019 (H1N1)pdm09 – like strain (A/Victoria/2570/2019, IVR-215)
A/Hong Kong/2671/2019 (H3N2) – like strain (A/Hong Kong/2671/2019, IVR-208)
B/Washington/02/2019 – like strain (B/Washington/02/2019, wild type)
B/Phuket/3073/2013 – like strain (B/Phuket/3073/2013, wild type)

Content

Indication

the prevention of influenza disease caused by the two influenza A virus
subtypes and the two influenza B virus types contained in the vaccine for:
– active immunisation of adults, including pregnant women, and children from 6 months of age.
– passive protection of infants less than 6 months of age and born to women vaccinated during
pregnancy

Viviant

Ingredient

bazedoxifene acetate

Content

bazedoxifene acetate(as bazedoxifene) 20mg

Indication

Treatment and prevention of osteoporosis in postmenopausal women.

**However, this drug reduced the incidence of spinal fractures, but the effectiveness for non-spinal fractures has not been established.

Vyxeos liposomal inj.

Ingredient

Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine

Content

Powder for concentrate for solution for infusion.
Purple, lyophilised cake.

Indication

Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute
myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

X-Pain ER Semi Tab.

Ingredient

Acetaminophen
Tramadol Hydrochloride

Content

Acetaminophen　325mg
Tramadol Hydrochloride　37.5mg

Indication

Moderate-severe acute and chronic pain.